MarketInOut Stock Screener Log In | Sign Up
 

Scilex Holding Co

NASDAQ • Healthcare • Drug Manufacturers - General • Quote as of 10/23/2026
Scilex Holding Co stock price and volume chart

Company Profile

IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeNASDAQ
Market Capitalization17.38 mln
Float6.21 mln
Earnings Date11/13/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-9.08
Highly reliable

Relative Strength

13 / 100
Significantly lagging

Pre-Tax Margin

-1,470%
Severely loss-making

ROE

190
Extraordinary

Altman Z-Score

-13.89
Deeply distressed

Business Description

Scilex Holding Company is a Palo Alto-based healthcare business focused on developing and selling non-opioid treatments for both short-term and long-term pain. Its current lineup includes a lidocaine skin patch for post-shingles nerve pain, a liquid migraine treatment, and an oral solution for preventing gout flare-ups. The company is also advancing three pipeline treatments targeting sciatica, neck and back pain, and fibromyalgia, each having completed at least one clinical trial phase. Scilex works with partners in Japan and the United States to support product development and manufacturing.

Key Fundamentals

EPS-48.24
ROE190
RPS3.64
ROIC-93.59
ROA-176
Interest Cover-17.65
EBITDA, mln-440
EV / EBITDA-0.31
EV / EBIT-0.30
Revenue, mln31.61
EV / Revenue4.25

Quote Details

Last 2.35
Change -0.12 (-4.86%)
Open 2.44
Volume 35,222
Turnover 82,772
Average Volume 46,420

Financial Ratios

Pre-Tax Profit Margin-1,470
Current Ratio0.07
Price / Sales1.17

Financial Strength

Altman Z-Score-13.89
Piotroski F-Score 2 / 9
Beneish M-Score-9.08
Short Ratio5.67
Short % of Float3.09

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -16.96% 4 / 100   
1 Month -52.43% 4 / 100   
2 Months -69.24% 4 / 100   
6 Months -64.87% 8 / 100   
1 Year -82.16% 8 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog